UNCY Investors Invited to Lead Class Action Against Unicycive Therapeutics for Securities Fraud

The Rosen Law Firm, a prominent global advocate for investor rights, recently announced an important opportunity for shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Between March 29, 2024, and June 27, 2025, purchasers of the company's securities may be eligible to join a class action lawsuit seeking justice for alleged securities fraud. If you invested in Unicycive during this designated period, you may be entitled to significant compensation at no upfront cost, thanks to a contingency fee agreement.

Class Action Details

A class action lawsuit has already been filed, presenting a chance for investors to represent themselves as lead plaintiffs—a position afforded to those who act on behalf of other class members in the ongoing litigation. Those interested in taking on this responsibility must submit their motion to the court by October 14, 2025.

In order to join the ongoing lawsuit, individuals can fill out a form on the Rosen Law Firm's website or reach out to Phillip Kim at the firm for further assistance. This is a critical step for those who feel they have been wronged by the alleged misstatements made by Unicycive regarding its capabilities in meeting FDA compliance requirements.

Why Act Now?

Rosen Law Firm emphasizes the importance of selecting experienced legal counsel when navigating such legal matters. With a history of achieving substantial settlements for investors—over $438 million recovered in 2019 alone—this firm comes highly recommended for its consistent success in securities class action lawsuits. It was ranked number one by ISS Securities Class Action Services for settlements in 2017 and has been a leader in this field since then.

Case Overview

The lawsuit primarily claims that Unicycive’s executives made several misleading statements regarding their readiness to comply with U.S. FDA manufacturing requirements. Allegedly, Unicycive also overestimated the regulatory prospects for its oxylanthanum carbunate (OLC) New Drug Application (NDA), impacting the credibility of their public communications. When the truth became evident, investors faced significant financial losses, and the lawsuit seeks to address this injustice.

While no class has yet been certified, potential class members are encouraged to join the action to protect their rights. They have the option to either remain passive participants or engage actively. It's crucial to remember that whether or not someone serves as a lead plaintiff, their ability to share in any future recovery will not be affected.

Next Steps

For further information or to express your intent to join the lawsuit, visit Rosen Law Firm's webpage or contact Phillip Kim, Esq. by phone at 866-767-3653 or via email at [email protected].

Stay informed about updates or developments regarding this class action by following Rosen Law Firm on LinkedIn, Twitter, or Facebook. This is a pivotal moment for UNCY investors to assert their rights and seek potential recovery for their losses.

Attorney Advertising: Past results do not guarantee a similar outcome.